Concepedia

Patricio Yañez

PY

Statistics

Publications

17

Citations

5.5K

H-Index

15

Active since

2020

Affiliations

Universidad de La Frontera(Current)

National Cancer Center Hospital East

Memorial Sloan Kettering Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Peking University Cancer Hospital

Patricio Yañez is an author at Universidad de La Frontera specializing in oncology, medicine, and gastrointestinal oncology.

ORCID

Publications per year

2020–2025

16

Publications

17

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

, , +16

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez et al. · Nature · 2021 · 689 citations · Full text

, , +17

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai et al. · The Lancet · 2023 · 467 citations

, , +17

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

, , +17

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · The Lancet Oncology · 2023 · 339 citations

, , +16

1–5 of 17